01 Mening Loehr 508
Document text
Introduction to Session: Meningococcal Vaccines Jamie Loehr, MD Chair, ACIP Meningococcal/Hib Vaccines Work Group June 28, 2024National Center for Immunization & Respiratory Diseases 1 ACIP Meningococcal/Hib Vaccines Work Group ▪ ACIP Members on the WG •Jamie Loehr (Chair) •Wilbur Chen ▪ Ex Officio WG Members •Margaret Bash (FDA) •Matthew Clark (IHS) •Xin-Xing Gu (NIH) ▪ WG Liaisons and Consultants •Amra Resic (AAFP) •Mary Healy (AAP) •Barb Fluty (ACHA) •Karyn Lyons (AIM) •Paul Cieslak (CSTE) •Kathy Hsu (IDSA) •Pamela Doyon -Plourde (NACI) •Jeff Goad (NFID) •Jessica Cataldi (PIDS) •Amy Middleman (SAHM) •Kathy Poehling (Wake Forest) •Lynn Bahta (Minnesota Department of Health) •David Stephens (Emory) ▪ GRADE/ EtR Support •Doug Campos -Outcalt (Arizona) •Rebecca Morgan (Case Western Reserve)▪ CDC Contributors •Sarah Schillie (DBD/NCIRD) •Jennifer Collins (DBD/NCIRD) •Lucy McNamara (DBD/NCIRD) •LeAnne Fox (DBD/NCIRD) •Susan Hariri (DBD/NCIRD) •Amy Rubis (DBD/NCIRD) •Noele Nelson (DBD/NCIRD) •Alison Albert (DBD/NCIRD) •Shelby Miller (DBD/NCIRD) •Michelle Hughes (DBD/NCIRD) •Brian Edwards (DBD/NCIRD) •Isha Berry (DBD/NCIRD) •Madhura Vachon (DBD/NCIRD) •Gabrielle Cooper (DBD/NCIRD) •Xiaoyu Dong (ISD/NCIRD) •Andrew Leidner (ISD/NCIRD) •Ismael Ortega -Sanchez (CORVD/NCIRD) •Liz Velazquez (ISD/NCIRD) •Marc Fischer (DIDRI/NCEZID) •Jonathan Duffy (DHQP/NCEZID) •Pedro Moro (DHQP/NCEZID) •Tanya Myers (DHQP/NCEZID) •Leslie Lee (OD/NCIRD) •Manisha (Mo) Patel (OD/NCIRD) •Jessica MacNeil (ACIP Secretariat) •Hannah Rosenblum (ACIP Secretariat) •Melinda Wharton (ACIP Secretariat) 2 Two Terms of Reference ▪GSK’s MenABCWY Vaccine ▪Revisiting the adolescent meningococcal vaccine schedule 3 4Today’s agenda All topics will be presented for information and discussionTopic Presenter Epidemiology Updates Ms. Amy Rubis (CDC/NCIRD) GSK Pentavalent Vaccine Immunogenicity and SafetyDr. Wendy Sohn (GSK) Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB VaccinationDr. Sarah Schillie (CDC/NCIRD) Policy Questions for GSK’s MenABCWY (Pentavalent) Vaccine ▪Should the pentavalent vaccine be included as an option for MenACWY /MenB vaccination in people currently recommended to receive both vaccines at the same visit? •For example, 16 year -olds* ▪Should the pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only? •For example, 11 –12 year -olds ▪Should the pentavalent vaccine be included as an option for people currently recommended to receive MenB only? • For example, during a serogroup B outbreak *16 year -olds who receive the MenB vaccine based on shared clinical decision -making 5 Upcoming ACIP Meetings ▪October 2024 •GRADE/ EtR •Cost -effectiveness analysis ▪February 2025 •Anticipated Vote 6